Cargando…
Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy
SIMPLE SUMMARY: Lymph node invasion represents a poor prognostic factor after primary radical prostatectomy for prostate cancer. However, its impact on oncologic outcomes in salvage radical prostatectomy patients is unknown. Within this study we investigated the impact of lymph node invasion and dis...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296518/ https://www.ncbi.nlm.nih.gov/pubmed/37370733 http://dx.doi.org/10.3390/cancers15123123 |
_version_ | 1785063669266120704 |
---|---|
author | Preisser, Felix Incesu, Reha-Baris Rajwa, Pawel Chlosta, Marcin Ahmed, Mohamed Abreu, Andre Luis Cacciamani, Giovanni Ribeiro, Luis Kretschmer, Alexander Westhofen, Thilo Smith, Joseph A. Graefen, Markus Calleris, Giorgio Raskin, Yannic Gontero, Paolo Joniau, Steven Sanchez-Salas, Rafael Shariat, Shahrokh F. Gill, Inderbir Karnes, Robert Jeffrey Cathcart, Paul Van Der Poel, Henk Marra, Giancarlo Tilki, Derya |
author_facet | Preisser, Felix Incesu, Reha-Baris Rajwa, Pawel Chlosta, Marcin Ahmed, Mohamed Abreu, Andre Luis Cacciamani, Giovanni Ribeiro, Luis Kretschmer, Alexander Westhofen, Thilo Smith, Joseph A. Graefen, Markus Calleris, Giorgio Raskin, Yannic Gontero, Paolo Joniau, Steven Sanchez-Salas, Rafael Shariat, Shahrokh F. Gill, Inderbir Karnes, Robert Jeffrey Cathcart, Paul Van Der Poel, Henk Marra, Giancarlo Tilki, Derya |
author_sort | Preisser, Felix |
collection | PubMed |
description | SIMPLE SUMMARY: Lymph node invasion represents a poor prognostic factor after primary radical prostatectomy for prostate cancer. However, its impact on oncologic outcomes in salvage radical prostatectomy patients is unknown. Within this study we investigated the impact of lymph node invasion and dissection on the oncologic outcomes after salvage prostatectomy. Our results show that lymph node invasion represents are poor prognostic factor after salvage prostatectomy. Conversely, we recorded no benefit for lymph node dissection compared to no lymph node dissection during salvage prostatectomy. These findings underline the need for a cautious indication of lymph node dissection in salvage prostatectomy patients as well as strict postoperative monitoring of patients with lymph node invasion. ABSTRACT: Background: Lymph node invasion (LNI) represents a poor prognostic factor after primary radical prostatectomy (RP) for prostate cancer (PCa). However, the impact of LNI on oncologic outcomes in salvage radical prostatectomy (SRP) patients is unknown. Objective: To investigate the impact of lymph node dissection (LND) and pathological lymph node status (pNX vs. pN0 vs. pN1) on long-term oncologic outcomes of SRP patients. Patients and methods: Patients who underwent SRP for recurrent PCa between 2000 and 2021 were identified from 12 high-volume centers. Kaplan–Meier analyses and multivariable Cox regression models were used. Endpoints were biochemical recurrence (BCR), overall survival (OS), and cancer-specific survival (CSS). Results: Of 853 SRP patients, 87% (n = 727) underwent LND, and 21% (n = 151) harbored LNI. The median follow-up was 27 months. The mean number of removed lymph nodes was 13 in the LND cohort. At 72 months after SRP, BCR-free survival was 54% vs. 47% vs. 7.2% for patients with pNX vs. pN0 vs. pN1 (p < 0.001), respectively. At 120 months after SRP, OS rates were 89% vs. 81% vs. 41% (p < 0.001), and CSS rates were 94% vs. 96% vs. 82% (p = 0.02) for patients with pNX vs. pN0 vs. pN1, respectively. In multivariable Cox regression analyses, pN1 status was independently associated with BCR (HR: 1.77, p < 0.001) and death (HR: 2.89, p < 0.001). Conclusions: In SRP patients, LNI represents an independent poor prognostic factor. However, the oncologic benefit of LND in SRP remains debatable. These findings underline the need for a cautious LND indication in SRP patients as well as strict postoperative monitoring of SRP patients with LNI. |
format | Online Article Text |
id | pubmed-10296518 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102965182023-06-28 Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy Preisser, Felix Incesu, Reha-Baris Rajwa, Pawel Chlosta, Marcin Ahmed, Mohamed Abreu, Andre Luis Cacciamani, Giovanni Ribeiro, Luis Kretschmer, Alexander Westhofen, Thilo Smith, Joseph A. Graefen, Markus Calleris, Giorgio Raskin, Yannic Gontero, Paolo Joniau, Steven Sanchez-Salas, Rafael Shariat, Shahrokh F. Gill, Inderbir Karnes, Robert Jeffrey Cathcart, Paul Van Der Poel, Henk Marra, Giancarlo Tilki, Derya Cancers (Basel) Article SIMPLE SUMMARY: Lymph node invasion represents a poor prognostic factor after primary radical prostatectomy for prostate cancer. However, its impact on oncologic outcomes in salvage radical prostatectomy patients is unknown. Within this study we investigated the impact of lymph node invasion and dissection on the oncologic outcomes after salvage prostatectomy. Our results show that lymph node invasion represents are poor prognostic factor after salvage prostatectomy. Conversely, we recorded no benefit for lymph node dissection compared to no lymph node dissection during salvage prostatectomy. These findings underline the need for a cautious indication of lymph node dissection in salvage prostatectomy patients as well as strict postoperative monitoring of patients with lymph node invasion. ABSTRACT: Background: Lymph node invasion (LNI) represents a poor prognostic factor after primary radical prostatectomy (RP) for prostate cancer (PCa). However, the impact of LNI on oncologic outcomes in salvage radical prostatectomy (SRP) patients is unknown. Objective: To investigate the impact of lymph node dissection (LND) and pathological lymph node status (pNX vs. pN0 vs. pN1) on long-term oncologic outcomes of SRP patients. Patients and methods: Patients who underwent SRP for recurrent PCa between 2000 and 2021 were identified from 12 high-volume centers. Kaplan–Meier analyses and multivariable Cox regression models were used. Endpoints were biochemical recurrence (BCR), overall survival (OS), and cancer-specific survival (CSS). Results: Of 853 SRP patients, 87% (n = 727) underwent LND, and 21% (n = 151) harbored LNI. The median follow-up was 27 months. The mean number of removed lymph nodes was 13 in the LND cohort. At 72 months after SRP, BCR-free survival was 54% vs. 47% vs. 7.2% for patients with pNX vs. pN0 vs. pN1 (p < 0.001), respectively. At 120 months after SRP, OS rates were 89% vs. 81% vs. 41% (p < 0.001), and CSS rates were 94% vs. 96% vs. 82% (p = 0.02) for patients with pNX vs. pN0 vs. pN1, respectively. In multivariable Cox regression analyses, pN1 status was independently associated with BCR (HR: 1.77, p < 0.001) and death (HR: 2.89, p < 0.001). Conclusions: In SRP patients, LNI represents an independent poor prognostic factor. However, the oncologic benefit of LND in SRP remains debatable. These findings underline the need for a cautious LND indication in SRP patients as well as strict postoperative monitoring of SRP patients with LNI. MDPI 2023-06-09 /pmc/articles/PMC10296518/ /pubmed/37370733 http://dx.doi.org/10.3390/cancers15123123 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Preisser, Felix Incesu, Reha-Baris Rajwa, Pawel Chlosta, Marcin Ahmed, Mohamed Abreu, Andre Luis Cacciamani, Giovanni Ribeiro, Luis Kretschmer, Alexander Westhofen, Thilo Smith, Joseph A. Graefen, Markus Calleris, Giorgio Raskin, Yannic Gontero, Paolo Joniau, Steven Sanchez-Salas, Rafael Shariat, Shahrokh F. Gill, Inderbir Karnes, Robert Jeffrey Cathcart, Paul Van Der Poel, Henk Marra, Giancarlo Tilki, Derya Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title_full | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title_fullStr | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title_full_unstemmed | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title_short | Oncologic Outcomes of Lymph Node Dissection at Salvage Radical Prostatectomy |
title_sort | oncologic outcomes of lymph node dissection at salvage radical prostatectomy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10296518/ https://www.ncbi.nlm.nih.gov/pubmed/37370733 http://dx.doi.org/10.3390/cancers15123123 |
work_keys_str_mv | AT preisserfelix oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT incesurehabaris oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT rajwapawel oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT chlostamarcin oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT ahmedmohamed oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT abreuandreluis oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT cacciamanigiovanni oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT ribeiroluis oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT kretschmeralexander oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT westhofenthilo oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT smithjosepha oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT graefenmarkus oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT callerisgiorgio oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT raskinyannic oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT gonteropaolo oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT joniausteven oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT sanchezsalasrafael oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT shariatshahrokhf oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT gillinderbir oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT karnesrobertjeffrey oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT cathcartpaul oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT vanderpoelhenk oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT marragiancarlo oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy AT tilkiderya oncologicoutcomesoflymphnodedissectionatsalvageradicalprostatectomy |